TP53 and CDKN2A mutations in patients with early-stage lung squamous cell carcinoma: an analysis of the correlations and prognostic outcomes.

Wang, Peiyuan; Wang, Feng; He, Hao; Chen, Yujie; Lin, Hui; Chen, Peng; Chen, Xiaofeng; Liu, Shuoyan

Wang, Peiyuan; Wang, Feng; He, Hao; Chen, Yujie; Lin, Hui; Chen, Peng; Chen, Xiaofeng; Liu, Shuoyan.

Afiliação

Wang P; Department of Thoracic Oncology Surgery, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, China.
Wang F; Fujian Key Laboratory of Translational Cancer Medicine, Fuzhou, China.
He H; Fujian Provincial Key Laboratory of Tumor Biotherapy, Fuzhou, China.
Chen Y; Department of Thoracic Oncology Surgery, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, China.
Lin H; Department of Thoracic Oncology Surgery, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, China.
Chen P; Department of Thoracic Oncology Surgery, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, China.
Chen X; Department of Thoracic Oncology Surgery, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, China.
Liu S; Department of Thoracic Oncology Surgery, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, China.

Ann Transl Med ; 9(16): 1330, 2021 Aug.

Article em En | MEDLINE | ID: mdl-34532467

Palavras-chave

Tumor protein p53 (TP53); cyclin dependent kinase inhibitor 2A (CDKN2A); lung squamous cell carcinoma (LUSC); mutation; prognosis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Ann Transl Med Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google